The primary hypothesis is to investigate whether a low calorie diet for 7 weeks followed by continuous lifestyle advice is an effective option to achieve an improvement in glucose control as measured by HbA1c after 52 and 104 weeks as compared to baseline values in obese type 2 diabetes patients on either tablet or insulin treatment. The secondary hypothesis is to investigate whether the weight reduction therapy also has significant impact on various anthropometric, clinical and metabolic parameters associated with obesity.
This is a prospective study on the impact of low calorie diet followed by a weight maintenance program on 12 and 24 month glucose control in a cohort of patients with obesity and diabetes mellitus. The study will consist of 3 phases: 1. Screening period (up to 12 weeks). 2. Low calorie diet weeks 1-9. Seven weeks of low-calorie diet including 800 kcal/day followed by 2 weeks of gradual introduction of normal diet of eventually 1500-2000 kcal/day, i.e. 600 kcal/day deficit, based on present body weight and sex. At entry of the LCD-period, all medication for diabetes mellitus, with the exception of metformin and insulin, will be removed. During the LCD-period, insulin treatment will gradually be reduced and, if possible, withdrawn. Patients will perform daily self-monitoring of fasting and post-prandial plasma glucose. At each visit, which will take place once a week, the patients will see a physician, a nurse and a dietician. The patients will be given specific advice to increase their physical activity. Patients will remain on medication for dyslipidemia. Blood pressure will be measured at each visit and in case of blood pressure \< 110/70 mmHg and/or in case of symptoms associated with hypotension including dizziness, medication for hypertension will be reduced or removed. 3. Weight-maintenance program weeks 10-52. 4. Follow up visits at months 15, 18, 21 and 24.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
40
1. Low calorie diet of 800 kcal/day for 7 weeks. 2. Life style intervention for the remaining study period
Karolinska University Hospital
Stockholm, Sweden
Change from Baseline in HbA1c (mmol/mol) at 12 and 24 months
Time frame: 12 months and 24 months
Change from Baseline in BMI (kg/m2) at 7 weeks, 6,12, and 24 months
Time frame: 7 weeks, 6, 12 and 24 months
Change from Baseline in Liver Fat (Controlled Attenuation Parameter, db/m) at 7 weeks, 6, 12 and 24 months
Liver Fat Measured by Fibroscan
Time frame: 7 weeks, 6, 12 and 24 months
Change from Baseline in Cholesterol (mmo/l) and Triglycerides (mmol/l) at 7 weeks, 6, 12 and 24 months
Time frame: 7 weeks, 6,12 and 24 months
Change from Baseline in 2-hour Glucose (mmol/l) and Insulin (mU/l) by Glucose tolerance test at 7 weeks, 6, 12 and 24 months
Glucose tolerance test: oral administration of 75 g Glucose
Time frame: 7 weeks, 6,12, 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.